{"commentary":{"count":34,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":29,"podcast":3,"youtube":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03367702\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT03367702","nct_id":"NCT03367702","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03367702. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients undergo IMRT once daily for 5 fractions per week for 20 or 28 fractions over less than 32 business days.","label":"Arm I (IMRT)","type":"ACTIVE_COMPARATOR"},{"description":"Patients undergo SBRT at least every other day for 2-3 fractions per week over less than 17 business days.","label":"Arm II (SBRT)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2027-12-01","type":"ESTIMATED"},"conditions":["Stage II Prostate Adenocarcinoma AJCC v7"],"enrollment":{"count":692,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Intensity-Modulated Radiation Therapy","type":"RADIATION"},{"name":"Quality-of-Life Assessment","type":"OTHER"},{"name":"Questionnaire Administration","type":"OTHER"},{"name":"Stereotactic Body Radiation Therapy","type":"RADIATION"}],"last_update":"2026-01-15","lead_sponsor":"NRG Oncology","official_title":"Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-12-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Incidence of patients-reported gastrointestinal and genitourinary toxicity","timeFrame":"Up to 2 years"},{"measure":"Disease free survival","timeFrame":"Time to biochemical failure (Phoenix definition), local failure, regional failure, distant metastasis, or death from any cause, assessed up to 2 years"}],"references":[{"citation":"Ellis RJ, Pugh SL, Yu JB, Feng FY, Konski AA, Grubb RL 3rd, Wallace RE, Gladstone DJ, Menard C, Miccio JA, Frazier AJ, Pennington JD, Michalski JM, Spratt DE, Martinez A, Morgan SC, Mihai A, Solanki AA, Amjad A, Straza MW, Delouya G, Schroeder TM, Marshall DT, Kapadia N, Patel AN, Cescon TP, El-Gayed A, Yoon HA, Paulus R, Sandler HM; NRG-GU005 Collaborative Authors. Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: A Randomized Clinical Trial. JAMA. 2026 Aug 13:e2612627. doi: 10.1001/jama.2026.12627. Online ahead of print.","pmid":"42593775","type":"DERIVED"},{"citation":"Alley S, Tonneau M, Olivie D, Tempany-Afdhal CM, Choyke PL, Turkbey IB, van der Heide UA, Ellis RJ, Kadoury S, Boike TP, Pennington JD, Frazier A, Lawton CAF, Leong N, Mihai AM, Morgan SC, Solanki AA, Michalski JM, Feng FY, Sandler HM, Menard C. Assessing Quality and Adherence to PI-RADSv2.1 Minimum Technical Standards of Prostate MRI in NRG-GU005. J Magn Reson Imaging. 2026 Feb;63(2):464-474. doi: 10.1002/jmri.70142. Epub 2025 Oct 8.","pmid":"41063518","type":"DERIVED"},{"citation":"Alley S, Jackson E, Olivie D, Van der Heide UA, Menard C, Kadoury S. Effect of magnetic resonance imaging pre-processing on the performance of model-based prostate tumor probability mapping. Phys Med Biol. 2022 Dec 13;67(24). doi: 10.1088/1361-6560/ac99b4.","pmid":"36223780","type":"DERIVED"}],"start_date":{"date":"2018-02-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT03367702"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03367702"}